To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation
Clinical trial NCT05555212 · UNKNOWN
Trial details
- NCT number
- NCT05555212
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-25
- Primary completion
- 2024-12-31
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.